Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Karyopharm Therapeutics Inc. (KPTI)
USD9.64
-0.37 (-3.70%)
US NASDAQ Healthcare Biotechnology
Address
85 Wells Avenue 2459
Newton, MA, US
Newton, MA, US
CEO
Richard A. Paulson
Website
karyopharm.com
IPO
2013-11-06
CIK 1503802 ISIN US48576U2050
Description
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.64
-0.37 (-3.70%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
494.1K
Beta
0.82
Float Shares
7.97M
Free Float %
93.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.56% | +0.34% | +5.33% | +3.73% | +56.69% | +20.92% | +83.51% | -76.08% | -93.53% | -92.57% | -96.30% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (20 ratings, all time)
Buy
Price Targets & DCF
Current price
9.64
Low
12.00
+24.5%
Consensus
17.25
+78.9%
Median
14.50
+50.4%
High
28.00
+190.5%
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
14.50
+50.4%
|
| Last Quarter | 3 |
19.00
+97.1%
|
| Last Year | 9 |
15.78
+63.7%
|
| All Time | 13 |
13.23
+37.2%
|
Quality scores
Altman Z-Score
-20.08
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+0.6% Q1'26: +16.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-90.5% Q1'26: +55.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-74.0% Q1'26: -64.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-62.1% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+34.6% Q1'26: +191.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.58× Q1'26: -0.16× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
250.0K
est: 280.0K (-10.7%)
|
154.0K
est: 108.3K (+42.2%)
|
1.61M
est: 82.1K (+1,854.2%)
|
30.34M
est: 30.55M (-0.7%)
|
40.89M
est: 39.04M (+4.8%)
|
108.09M
est: 101.43M (+6.6%)
|
209.82M
est: 133.12M (+57.6%)
|
157.07M
est: 157.96M (-0.6%)
|
146.03M
est: 145.67M (+0.3%)
|
145.24M
est: 150.37M (-3.4%)
|
146.07M
est: 147.10M (-0.7%)
|
137.49M
127.98M – 155.34M
-6.5% YoY
|
157.71M
140.34M – 175.09M
+14.7% YoY
|
235.24M
211.66M – 269.79M
+49.2% YoY
|
422.82M
380.44M – 484.92M
+79.7% YoY
|
619.50M
557.41M – 710.49M
+46.5% YoY
|
| EBITDA |
-118.44M
est: -191.8K (-61,638.1%)
|
-108.72M
est: -74.2K (-146,418.3%)
|
-128.21M
est: -56.3K (-227,736.2%)
|
-175.15M
est: -172.15M (-1.7%)
|
-182.93M
est: -179.54M (-1.9%)
|
-167.85M
est: -157.81M (-6.4%)
|
-96.99M
est: -18.12M (-435.2%)
|
-139.31M
est: -3.84M (-3,523.7%)
|
-118.42M
est: -88.71M (-33.5%)
|
-38.60M
est: -91.57M (+57.8%)
|
-90.41M
est: -89.58M (-0.9%)
|
-83.73M
-94.60M – -77.94M
+6.5% YoY
|
-96.04M
-106.62M – -85.46M
-14.7% YoY
|
-143.25M
-164.29M – -128.90M
-49.2% YoY
|
-257.48M
-295.30M – -231.68M
-79.7% YoY
|
-377.25M
-432.66M – -339.44M
-46.5% YoY
|
| EBIT |
-119.08M
est: -192.6K (-61,721.7%)
|
-109.44M
est: -74.5K (-146,798.6%)
|
-128.92M
est: -56.5K (-228,090.9%)
|
-175.89M
est: -176.82M (+0.5%)
|
-183.90M
est: -186.13M (+1.2%)
|
-168.82M
est: -161.54M (-4.5%)
|
-97.77M
est: -18.92M (-416.7%)
|
-139.93M
est: -4.16M (-3,264.1%)
|
-118.95M
est: -89.16M (-33.4%)
|
-38.94M
est: -92.04M (+57.7%)
|
-90.71M
est: -90.04M (-0.7%)
|
-84.16M
-95.08M – -78.34M
+6.5% YoY
|
-96.54M
-107.17M – -85.90M
-14.7% YoY
|
-143.99M
-165.14M – -129.56M
-49.2% YoY
|
-258.81M
-296.82M – -232.87M
-79.7% YoY
|
-379.20M
-434.89M – -341.19M
-46.5% YoY
|
| Net Income |
-118.18M
est: -26.06M (-353.6%)
|
-109.58M
est: -340.86M (+67.9%)
|
-128.98M
est: -322.33M (+60.0%)
|
-178.41M
est: -175.08M (-1.9%)
|
-199.59M
est: -196.26M (-1.7%)
|
-196.27M
est: -184.62M (-6.3%)
|
-124.09M
est: -57.42M (-116.1%)
|
-165.29M
est: -51.81M (-219.0%)
|
-143.10M
est: -8.70M (-1,544.5%)
|
-76.42M
est: -123.57M (+38.2%)
|
-196.04M
est: -133.19M (-47.2%)
|
-49.30M
-65.31M – -33.29M
+63.0% YoY
|
-33.37M
-55.79M – -10.95M
+32.3% YoY
|
-21.92M
-38.06M – -5.77M
+34.3% YoY
|
18.51M
16.10M – 22.04M
+184.4% YoY
|
38.71M
33.67M – 46.10M
+109.2% YoY
|
| SGA |
21.58M
est: 250.8K (+8,504.9%)
|
23.95M
est: 97.0K (+24,586.1%)
|
24.87M
est: 73.6K (+33,705.5%)
|
48.85M
est: 27.37M (+78.5%)
|
105.42M
est: 34.97M (+201.5%)
|
126.42M
est: 90.86M (+39.1%)
|
143.85M
est: 119.24M (+20.6%)
|
145.40M
est: 141.49M (+2.8%)
|
131.88M
est: 117.39M (+12.3%)
|
115.44M
est: 121.18M (-4.7%)
|
105.21M
est: 118.54M (-11.3%)
|
110.80M
103.14M – 125.19M
-6.5% YoY
|
127.10M
113.10M – 141.10M
+14.7% YoY
|
189.58M
170.58M – 217.42M
+49.2% YoY
|
340.75M
306.60M – 390.79M
+79.7% YoY
|
499.25M
449.21M – 572.58M
+46.5% YoY
|
| EPS |
-49.80
est: -3.21 (-1,452.8%)
|
-43.80
est: -41.96 (-4.4%)
|
-42.15
est: -39.68 (-6.2%)
|
-47.11
est: -45.65 (-3.2%)
|
-48.32
est: -46.99 (-2.8%)
|
-40.87
est: -41.16 (+0.7%)
|
-24.75
est: -39.24 (+36.9%)
|
-30.28
est: -28.40 (-6.6%)
|
-18.79
est: -0.77 (-2,332.9%)
|
-9.41
est: -10.31 (+8.7%)
|
-17.93
est: -12.22 (-46.7%)
|
-4.31
-5.97 – -3.04
+64.7% YoY
|
-3.05
-5.10 – -1.00
+29.2% YoY
|
-1.71
-3.48 – -0.53
+44.0% YoY
|
1.69
1.47 – 2.02
+199.1% YoY
|
3.54
3.08 – 4.22
+109.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-04-27 | Piper Sandler | Overweight | Overweight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-58.57M
OE per share TTM
-4.39
Owner's Yield
-29.89%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
13
Total invested
6.74M
Insider transactions (90d)
1
Beneficial owners (>5%)
39
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Avidity Capital Partners (GP) LLC | 11.35M | 9.90% | — | 11.35M | — | 11.35M | OO | Delaware | 2022-12-08 | ↗ |
| 2 | Avidity Capital Partners Fund (GP) LP | 11.35M | 9.90% | — | 11.35M | — | 11.35M | PN, OO | Delaware | 2022-12-08 | ↗ |
| 3 | Avidity Partners Management (GP) LLC | 11.35M | 9.90% | — | 11.35M | — | 11.35M | OO | Delaware | 2022-12-08 | ↗ |
| 4 | Avidity Partners Management LP | 11.35M | 9.90% | — | 11.35M | — | 11.35M | IA, PN | Delaware | 2022-12-08 | ↗ |
| 5 | David Witzke | 11.35M | 9.90% | — | 11.35M | — | 11.35M | IN | Delaware | 2022-12-08 | ↗ |
| 6 | Michael Gregory | 11.35M | 9.90% | — | 11.35M | — | 11.35M | IN | Delaware | 2022-12-08 | ↗ |
| 7 | Highbridge Capital Management, LLC | 9.74M | 7.20% | — | 9.74M | — | — | IA, OO | State of Delaware | 2024-10-25 | ↗ |
| 8 | (1) BlackRock, Inc. | 8.92M | 11.80% | 8.35M | — | 8.92M | — | HC | Delaware | 2022-01-27 | ↗ |
| 9 | The Vanguard Group - 23-1945930 | 8.71M | 7.60% | — | — | 8.48M | 227.9K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 10 | (1)Names of reporting persons. BlackRock, Inc. | 8.51M | 10.50% | — | — | — | — | HC | Delaware | 2023-01-20 | ↗ |
| 11 | David Rosen | 8.29M | 7.33% | — | 4.44M | — | — | IN | United States of America | 2023-02-10 | ↗ |
| 12 | LP | 8.29M | 7.33% | — | 8.29M | — | — | IA, PN | State of Delaware | 2023-02-10 | ↗ |
| 13 | Avidity Master Fund LP | 8.16M | 7.10% | — | 8.16M | — | 8.16M | PN, OO | Delaware | 2022-12-08 | ↗ |
| 14 | J. Wood Capital Advisors LLC | 6.87M | 5.50% | — | 6.87M | — | 6.87M | OO | California | 2024-05-23 | ↗ |
| 15 | Jason Wood | 6.87M | 5.50% | — | 6.87M | — | 6.87M | IN | California | 2024-05-23 | ↗ |
| 16 | STATE STREET CORPORATION | 5.51M | 7.30% | — | 5.37M | — | 5.51M | HC | BOSTON, MASSACHUSETTS | 2022-02-11 | ↗ |
| 17 | Czernik | 5.50M | 7.50% | — | 5.50M | — | 5.50M | HC | CYPRUS | 2021-02-16 | ↗ |
| 18 | Hadjimichael | 5.50M | 7.50% | — | 5.50M | — | 5.50M | HC | CYPRUS | 2021-02-16 | ↗ |
| 19 | Ltd. | 5.50M | 7.50% | — | 5.50M | — | 5.50M | CO | CYPRUS | 2021-02-16 | ↗ |
| 20 | Nikolaou | 5.50M | 7.50% | — | 5.50M | — | 5.50M | HC | CYPRUS | 2021-02-16 | ↗ |
| 21 | Smolokowski | 5.50M | 7.50% | — | 5.50M | — | 5.50M | HC | CYPRUS | 2021-02-16 | ↗ |
| 22 | Anthony Joonkyoo Yun, MD | 5.47M | 7.24% | — | 5.47M | — | 5.47M | HC, IN | USA | 2022-02-14 | ↗ |
| 23 | PAI LLC | 5.47M | 7.24% | — | 5.47M | — | 5.47M | IA, OO | California | 2022-02-14 | ↗ |
| 24 | Palo Alto Investors LP | 5.47M | 7.24% | — | 5.47M | — | 5.47M | IA, OO | California | 2022-02-14 | ↗ |
| 25 | Patrick Lee, MD | 5.47M | 7.24% | — | 5.47M | — | 5.47M | HC, IN | USA | 2022-02-14 | ↗ |
| 26 | Michael G. Kauffman | 4.08M | 5.20% | 1.91M | 2.16M | 1.91M | 2.16M | IN | — | 2022-02-11 | ↗ |
| 27 | Sharon Shacham | 4.08M | 5.20% | 2.16M | 1.91M | 2.16M | 1.91M | IN | — | 2022-02-11 | ↗ |
| 28 | SSGA FUNDS MANAGEMENT, INC. | 4.05M | 5.36% | — | 4.04M | — | 4.05M | IA | BOSTON, MASSACHUSETTS | 2022-02-11 | ↗ |
| 29 | Capital LP | 4.01M | 5.10% | — | 4.01M | — | 4.01M | IA | Delaware, USA | 2022-05-09 | ↗ |
| 30 | Capital Master LP | 4.01M | 5.10% | — | 4.01M | — | 4.01M | OO | Delaware, USA | 2022-05-09 | ↗ |
| 31 | Adage Capital Advisors, L.L.C. | 2.47M | 3.35% | — | 2.47M | — | — | OO | Delaware | 2021-02-11 | ↗ |
| 32 | Adage Capital Partners GP, L.L.C. | 2.47M | 3.35% | — | 2.47M | — | — | OO | Delaware | 2021-02-11 | ↗ |
| 33 | Adage Capital Partners, L.P. | 2.47M | 3.35% | — | 2.47M | — | — | PN | Delaware | 2021-02-11 | ↗ |
| 34 | Phillip Gross | 2.47M | 3.35% | — | 2.47M | — | — | IN | Delaware | 2021-02-11 | ↗ |
| 35 | Robert Atchinson | 2.47M | 3.35% | — | 2.47M | — | — | IN | Delaware | 2021-02-11 | ↗ |
| 36 | Consonance Capital Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 37 | Consonance Capital Opportunity Fund Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 38 | Consonance Capman GP LLC | — | 0.00% | — | — | — | — | HC, OO | Delaware USA | 2021-02-17 | ↗ |
| 39 | Mitchell Blutt | — | 0.00% | — | — | — | — | HC, IN | USA | 2021-02-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
13
-63 vs prev Q
New positions
5
Closed positions
62
Increased
7
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 1.49M +790.4K (+112.8%) | 10.98M +6.4M (+139.4%) | 8.30% +0.165 pp | 0.01% +0.004 pp | USD5.88 +25.2% | 4 qtrs — |
| 2 | OPALEYE MANAGEMENT INC. | 930.0K +930.0K (+100.0%) | 6.84M +6.8M (+100.0%) | 5.17% +5.174 pp | 0.90% +0.903 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 3 | VANGUARD GROUP INC | 559.6K +151.4K (+37.1%) | 4.12M +1.4M (+54.3%) | 3.11% -1.622 pp | 0.00% +0.000 pp | USD4.73 +55.6% | 4 qtrs — |
| 4 | IKARIAN CAPITAL, LLC | 544.6K +517.3K (+1,897.9%) | 4.01M +3.8M (+2,148.3%) | 3.03% +2.713 pp | 0.31% +0.295 pp | USD7.18 +2.5% | 4 qtrs — |
| 5 | SOLEUS CAPITAL MANAGEMENT, L.P. | 440.0K +440.0K (+100.0%) | 3.24M +3.2M (+100.0%) | 5.08% +5.076 pp | 0.12% +0.120 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 421.3K +— (+0.0%) | 3.10M +345.5K (+12.5%) | 2.34% -2.544 pp | 0.00% +0.000 pp | USD3.74 +96.8% | 4 qtrs — |
| 7 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 310.0K +310.0K (+100.0%) | 2.28M +2.3M (+100.0%) | 1.72% +1.725 pp | 0.04% +0.036 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 8 | BRAIDWELL LP | 303.4K +303.4K (+100.0%) | 2.23M +2.2M (+100.0%) | 1.69% +1.688 pp | 0.07% +0.071 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 9 | EXOME ASSET MANAGEMENT LLC | 295.5K +295.5K (+100.0%) | 2.18M +2.2M (+100.0%) | 2.70% +2.703 pp | 1.04% +1.040 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 10 | AMERIPRISE FINANCIAL INC | 276.9K +276.9K (+100.0%) | 2.04M +2.0M (+100.0%) | 2.53% +2.532 pp | 0.00% +0.001 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 11 | BOXER CAPITAL MANAGEMENT, LLC | 252.5K +252.5K (+100.0%) | 1.86M +1.9M (+100.0%) | 2.31% +2.309 pp | 0.41% +0.407 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 12 | BLACKROCK, INC. | 247.6K +15.6K (+6.7%) | 1.82M +305.1K (+20.1%) | 1.38% -1.314 pp | 0.00% +0.000 pp | USD3.97 +85.4% | 4 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 187.7K +94.4K (+101.2%) | 1.38M +771.6K (+126.4%) | 1.04% -0.038 pp | 0.00% +0.000 pp | USD5.58 +31.9% | 4 qtrs — |
| 14 | TWO SIGMA INVESTMENTS, LP | 148.8K +148.8K (+100.0%) | 1.10M +1.1M (+100.0%) | 0.83% +0.828 pp | 0.00% +0.002 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 147.7K +112.4K (+317.9%) | 1.09M +855.9K (+370.3%) | 0.82% +0.412 pp | 0.00% +0.000 pp | USD7.16 +2.8% | 4 qtrs — |
| 16 | BOOTHBAY FUND MANAGEMENT, LLC | 144.6K +144.6K (+100.0%) | 1.06M +1.1M (+100.0%) | 1.32% +1.323 pp | 0.02% +0.016 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 17 | CATALIO CAPITAL MANAGEMENT, LP | 143.0K +— (+0.0%) | 1.05M +117.2K (+12.5%) | 1.31% -0.351 pp | 0.19% +0.013 pp | USD3.74 +96.8% | 4 qtrs — |
| 18 | AVIDITY PARTNERS MANAGEMENT LP | 134.6K +— (+0.0%) | 990.4K +110.3K (+12.5%) | 1.55% -0.009 pp | 0.29% +0.085 pp | USD3.74 +96.8% | 4 qtrs — |
| 19 | MARSHALL WACE, LLP | 128.5K +— (+0.0%) | 945.4K +105.3K (+12.5%) | 0.71% -0.776 pp | 0.00% +0.000 pp | USD3.74 +96.8% | 4 qtrs — |
| 20 | GROUP ONE TRADING, L.P. | 102.4K +34.0K (+49.7%) | 753.8K +306.2K (+68.4%) | 0.57% -0.224 pp | 0.00% +0.001 pp | USD5.32 +38.3% | 3 qtrs — |
| 21 | C WORLDWIDE GROUP HOLDING A/S | 100.0K +— (+0.0%) | 736.0K +82.0K (+12.5%) | 1.15% -0.007 pp | 0.01% +0.003 pp | USD3.74 +96.8% | 4 qtrs — |
| 22 | WALLEYE CAPITAL LLC | 95.7K +95.7K (+100.0%) | 704.1K +704.1K (+100.0%) | 1.10% +1.104 pp | 0.00% +0.002 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 23 | TWO SIGMA ADVISERS, LP | 89.7K +89.7K (+100.0%) | 660.4K +660.4K (+100.0%) | 0.50% +0.499 pp | 0.00% +0.001 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 24 | UBS GROUP AG | 88.5K +28.8K (+48.2%) | 651.0K +260.7K (+66.8%) | 0.49% -0.200 pp | 0.00% +0.000 pp | USD5.08 +44.9% | 4 qtrs — |
| 25 | CITADEL ADVISORS LLC | 71.3K +25.0K (+54.0%) | 524.8K +222.0K (+73.3%) | 0.40% -0.141 pp | 0.00% +0.000 pp | USD6.83 +7.8% | 4 qtrs — |
| 26 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 65.9K +31.0K (+88.9%) | 484.8K +256.8K (+112.6%) | 0.37% -0.038 pp | 0.01% +0.005 pp | USD5.75 +28.0% | 3 qtrs — |
| 27 | CONTEXT CAPITAL MANAGEMENT, LLC | 63.0K +63.0K (+100.0%) | 463.6K +463.6K (+100.0%) | 0.73% +0.727 pp | 0.01% +0.012 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 28 | RENAISSANCE TECHNOLOGIES LLC | 59.9K -4.8K (-7.4%) | 441.0K +17.7K (+4.2%) | 0.33% -0.417 pp | 0.00% +0.000 pp | USD3.78 +94.7% | 4 qtrs — |
| 29 | QUADRATURE CAPITAL LTD | 59.7K +59.7K (+100.0%) | 439.5K +439.5K (+100.0%) | 0.33% +0.332 pp | 0.00% +0.005 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 30 | STATE STREET CORP | 58.9K +12.6K (+27.2%) | 433.8K +130.7K (+43.1%) | 0.33% -0.210 pp | 0.00% +0.000 pp | USD5.17 +42.4% | 4 qtrs — |
| 31 | ROYAL BANK OF CANADA | 58.0K +51.3K (+761.3%) | 427.0K +383.0K (+870.5%) | 0.32% +0.245 pp | 0.00% +0.000 pp | USD6.99 +5.3% | 4 qtrs — |
| 32 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 57.2K +57.2K (+100.0%) | 421.1K +421.1K (+100.0%) | 0.66% +0.660 pp | 0.00% +0.001 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 33 | JUMP FINANCIAL, LLC | 53.8K +53.8K (+100.0%) | 396.1K +396.1K (+100.0%) | 0.49% +0.492 pp | 0.00% +0.005 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 34 | DAFNA CAPITAL MANAGEMENT LLC | 51.0K +51.0K (+100.0%) | 375.4K +375.4K (+100.0%) | 0.47% +0.466 pp | 0.09% +0.087 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 35 | ADAR1 CAPITAL MANAGEMENT, LLC | 50.0K +25.0K (+100.0%) | 368.0K +204.5K (+125.1%) | 0.28% -0.012 pp | 0.03% +0.012 pp | USD6.95 +5.9% | 2 qtrs — |
| 36 | BANK OF AMERICA CORP /DE/ | 48.1K +48.0K (+51,057.4%) | 353.9K +353.3K (+57,449.1%) | 0.27% +0.266 pp | 0.00% +0.000 pp | USD7.35 +0.1% | 4 qtrs — |
| 37 | TREXQUANT INVESTMENT LP | 41.7K +41.7K (+100.0%) | 307.2K +307.2K (+100.0%) | 0.23% +0.232 pp | 0.00% +0.003 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 38 | SILVERBACK ASSET MANAGEMENT LLC | 40.0K +— (+0.0%) | 294.4K +32.8K (+12.5%) | 0.37% -0.098 pp | 0.04% +0.018 pp | USD3.90 +88.7% | 4 qtrs — |
| 39 | JANE STREET GROUP, LLC | 35.7K +35.7K (+100.0%) | 262.8K +262.8K (+100.0%) | 0.20% +0.199 pp | 0.00% +0.000 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 40 | SIMPLEX TRADING, LLC | 32.9K +27.0K (+460.7%) | 241.9K +203.9K (+536.6%) | 0.18% +0.115 pp | 0.00% +0.000 pp | USD6.82 +7.9% | 3 qtrs — |
| 41 | NORTHERN TRUST CORP | 29.0K +10.1K (+53.8%) | 213.6K +90.2K (+73.0%) | 0.27% +0.046 pp | 0.00% +0.000 pp | USD5.01 +46.9% | 4 qtrs — |
| 42 | PRELUDE CAPITAL MANAGEMENT, LLC | 28.7K +28.7K (+100.0%) | 211.4K +211.4K (+100.0%) | 0.16% +0.160 pp | 0.02% +0.016 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 43 | BAIRD FINANCIAL GROUP, INC. | 28.0K +2.1K (+7.9%) | 206.0K +36.4K (+21.5%) | 0.26% -0.045 pp | 0.00% +0.000 pp | USD5.76 +27.8% | 3 qtrs — |
| 44 | PERSISTENT ASSET PARTNERS LTD | 18.3K +18.3K (+100.0%) | 134.8K +134.8K (+100.0%) | 0.10% +0.102 pp | 0.06% +0.061 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 45 | TUDOR INVESTMENT CORP ET AL | 12.9K +12.9K (+100.0%) | 95.1K +95.1K (+100.0%) | 0.12% +0.118 pp | 0.00% +0.000 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 46 | XTX TOPCO LTD | 11.9K -2.5K (-17.3%) | 87.6K -6.6K (-7.0%) | 0.07% -0.101 pp | 0.00% -0.003 pp | USD4.52 +62.8% | 3 qtrs — |
| 47 | BANK OF NEW YORK MELLON CORP | 11.1K +1.0 (+0.0%) | 81.6K +9.1K (+12.5%) | 0.13% -0.001 pp | 0.00% +0.000 pp | USD3.74 +96.8% | 4 qtrs — |
| 48 | PRICE T ROWE ASSOCIATES INC /MD/ | 10.9K +— (+0.0%) | 81.0K +9.0K (+12.5%) | 0.06% -0.066 pp | 0.00% +0.000 pp | USD4.31 +70.8% | 3 qtrs — |
| 49 | MORGAN STANLEY | 8.9K -16.9K (-65.6%) | 65.2K -103.3K (-61.3%) | 0.05% -0.250 pp | 0.00% +0.000 pp | USD4.14 +77.8% | 4 qtrs — |
| 50 | BARCLAYS PLC | 4.1K +— (+0.0%) | 30.2K +3.4K (+12.5%) | 0.02% -0.025 pp | 0.00% +0.000 pp | USD3.74 +96.8% | 4 qtrs — |
| 51 | ACADIAN ASSET MANAGEMENT LLC | 3.7K +3.7K (+100.0%) | 27.0K +27.0K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 52 | TD WATERHOUSE CANADA INC. | 3.2K +— (+0.0%) | 23.5K +3.7K (+18.4%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD3.74 +96.8% | 4 qtrs — |
| 53 | JPMORGAN CHASE & CO | 1.7K +1.2K (+216.5%) | 12.8K +9.2K (+256.2%) | 0.02% +0.014 pp | 0.00% +0.000 pp | USD6.28 +17.2% | 4 qtrs — |
| 54 | CI PRIVATE WEALTH, LLC | 10.0K +10.0K (+100.0%) | 10.0K +10.0K (+100.0%) | 0.06% +0.056 pp | 0.00% +0.000 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 55 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 733.00 +733.0 (+100.0%) | 5.4K +5.4K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 56 | FMR LLC | 679.00 +— (+0.0%) | 5.0K +556.0 (+12.5%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD3.91 +88.2% | 4 qtrs — |
| 57 | ASPECT PARTNERS, LLC | 391.00 +391.0 (+100.0%) | 2.9K +2.9K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.001 pp | USD7.36 +0.0% | 1 qtrs NEW |
| 58 | ADVISOR GROUP HOLDINGS, INC. | 282.00 -64.0 (-18.5%) | 2.1K -336.0 (-13.9%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD3.74 +96.8% | 4 qtrs — |
| 59 | QUENT CAPITAL, LLC | 235.00 +4.0 (+1.7%) | 1.7K +219.0 (+14.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.55 +12.4% | 4 qtrs — |
| 60 | MB, LEVIS & ASSOCIATES, LLC | 100.00 +— (+0.0%) | 736.00 +82.0 (+12.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.74 +96.8% | 4 qtrs — |
| 61 | HARBOUR INVESTMENTS, INC. | 85.00 +— (+0.0%) | 626.00 +70.0 (+12.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.73 +97.3% | 4 qtrs — |
| 62 | BNP PARIBAS ARBITRAGE, SNC | 82.00 +— (+0.0%) | 604.00 +68.0 (+12.7%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.74 +96.8% | 4 qtrs — |
| 63 | SBI SECURITIES CO., LTD. | 74.00 +— (+0.0%) | 545.00 +61.0 (+12.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.73 +97.3% | 4 qtrs — |
| 64 | ACTIVEST WEALTH MANAGEMENT | 66.00 +— (+0.0%) | 486.00 +54.0 (+12.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.73 +97.3% | 4 qtrs — |
| 65 | ALLWORTH FINANCIAL LP | 26.00 +— (+0.0%) | 192.00 +21.0 (+12.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.69 +99.5% | 4 qtrs — |
| 66 | WEST BRANCH CAPITAL LLC | 3.00 +— (+0.0%) | 23.00 +3.0 (+15.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.67 +100.5% | 4 qtrs — |
| 67 | CIBC PRIVATE WEALTH GROUP, LLC | 3.00 +— (+0.0%) | 22.00 +2.0 (+10.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.67 +100.5% | 4 qtrs — |
| 68 | CITIGROUP INC | 1.00 -512.0 (-99.8%) | 7.00 -3.3K (-99.8%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD3.00 +145.3% | 4 qtrs — |
| 69 | GOLDMAN SACHS GROUP INC | — -24.9K (-100.0%) | — -162.7K (-100.0%) | 0.00% -0.289 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 70 | RISE ADVISORS, LLC | — -131.0 (-100.0%) | — -857.0 (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 71 | BRUCE G. ALLEN INVESTMENTS, LLC | — -22.0 (-100.0%) | — -144.0 (-100.0%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 72 | BELVEDERE TRADING LLC | — -500.0 (-100.0%) | — -3.3K (-100.0%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 73 | FORTITUDE FAMILY OFFICE, LLC | — -81.0 (-100.0%) | — -530.0 (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 74 | PITTENGER & ANDERSON INC | — -3.0 (-100.0%) | — -20.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 75 | TOWER RESEARCH CAPITAL LLC (TRC) | — -1.1K (-100.0%) | — -7.1K (-100.0%) | 0.00% -0.013 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 76 | GSA CAPITAL PARTNERS LLP | — -14.1K (-100.0%) | — -92.0K (-100.0%) | 0.00% -0.163 pp | 0.00% -0.008 pp | USD— | 3 qtrs SOLD |
| 77 | AFFINITY ASSET ADVISORS, LLC | — -157.6K (-100.0%) | — -1.0M (-100.0%) | 0.00% -1.828 pp | 0.00% -0.090 pp | USD— | 3 qtrs SOLD |
| 78 | ADVISORY SERVICES NETWORK, LLC | — -12.0 (-100.0%) | — -78.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 40 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.57% | 124.6K | 0.20% |
| 2 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.13% | 371.0K | 0.39% |
| 3 | iShares Micro-Cap ETF IWC | 0.05% | 692.1K | 0.60% |
| 4 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 337.9K | 0.20% |
| 5 | Franklin U.S. Small Cap Multifactor Index ETF FLQS | 0.01% | 6.5K | 0.35% |
| 6 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.01% | 332.4K | 0.34% |
| 7 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.57M | 0.24% |
| 8 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 20.9K | 0.25% |
| 9 | Global X - Russell 2000 ETF RSSL | 0.01% | 96.2K | 0.08% |
| 10 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 182.3K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
449.00
Cash buys
—
Cash sales
1.00
Net activity
-449
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | Rangwala Reshma | Officer | S-Sale | D | Common Stock | 449 | 8.94 | 4.0K | 56,290 | D | ↗ |
| 2026-03-02 | Rangwala Reshma | Officer | S-Sale | D | Common Stock | 5,066 | 9.41 | 47.7K | 56,739 | D | ↗ |
| 2026-03-02 | Poulton Stuart | Officer | S-Sale | D | Common Stock | 5,101 | 9.41 | 48.0K | 94,328 | D | ↗ |
| 2026-03-02 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 12,361 | 9.41 | 116.3K | 267,030 | D | ↗ |
| 2026-03-02 | Mano Michael | Officer | S-Sale | D | Common Stock | 3,526 | 9.41 | 33.2K | 93,964 | D | ↗ |
| 2026-03-02 | Cheng Sohanya Roshan | Officer | S-Sale | D | Common Stock | 4,604 | 9.41 | 43.3K | 107,317 | D | ↗ |
| 2026-02-17 | Poulton Stuart | Officer | S-Sale | D | Common Stock | 378 | 8.63 | 3.3K | 99,429 | D | ↗ |
| 2026-02-05 | Paulson Richard A. | Director / Officer | A-Award | A | Common Stock | 81,060 | 0.00 | — | 279,391 | D | ↗ |
| 2026-02-03 | Macomber Lori | Officer | S-Sale | D | Common Stock | 1,626 | 6.30 | 10.2K | 85,105 | D | ↗ |
| 2026-01-31 | Rangwala Reshma | Officer | A-Award | A | Common Stock | 32,415 | 0.00 | — | 61,805 | D | ↗ |
| 2026-01-31 | Poulton Stuart | Officer | A-Award | A | Common Stock | 32,415 | 0.00 | — | 99,807 | D | ↗ |
| 2026-01-31 | Mano Michael | Officer | A-Award | A | Common Stock | 32,415 | 0.00 | — | 97,490 | D | ↗ |
| 2026-01-31 | Macomber Lori | Officer | A-Award | A | Common Stock | 32,415 | 0.00 | — | 86,731 | D | ↗ |
| 2026-01-31 | Cheng Sohanya Roshan | Officer | A-Award | A | Common Stock | 32,415 | 0.00 | — | 111,921 | D | ↗ |
| 2026-01-28 | Abate Kristin | Officer | S-Sale | D | Common Stock | 50 | 7.03 | 351.50 | 22,622 | D | ↗ |
| 2026-01-27 | Abate Kristin | Officer | A-Award | A | Common Stock | 92 | 0.00 | — | 22,672 | D | ↗ |
| 2026-01-21 | Abate Kristin | Officer | S-Sale | D | Common Stock | 265 | 5.96 | 1.6K | 22,580 | D | ↗ |
| 2025-10-15 | Poulton Stuart | Officer | A-Award | A | Common Stock | 39,682 | 0.00 | — | 67,392 | D | ↗ |
| 2025-10-15 | Paulson Richard A. | Director / Officer | A-Award | A | Common Stock | 114,285 | 0.00 | — | 198,331 | D | ↗ |
| 2025-10-15 | Mano Michael | Officer | A-Award | A | Common Stock | 43,650 | 0.00 | — | 65,075 | D | ↗ |
| 2025-10-15 | Macomber Lori | Officer | A-Award | A | Common Stock | 43,650 | 0.00 | — | 54,316 | D | ↗ |
| 2025-10-15 | Cheng Sohanya Roshan | Officer | A-Award | A | Common Stock | 43,650 | 0.00 | — | 79,506 | D | ↗ |
| 2025-10-15 | Abate Kristin | Officer | A-Award | A | Common Stock | 12,799 | 0.00 | — | 22,845 | D | ↗ |
| 2025-10-01 | Abate Kristin | Officer | S-Sale | D | Common Stock | 362 | 6.30 | 2.3K | 10,046 | D | ↗ |
| 2025-09-15 | Rangwala Reshma | Officer | S-Sale | D | Common Stock | 408 | 6.43 | 2.6K | 29,390 | D | ↗ |
| 2025-09-15 | Poulton Stuart | Officer | S-Sale | D | Common Stock | 401 | 6.43 | 2.6K | 27,710 | D | ↗ |
| 2025-09-15 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 1,257 | 6.43 | 8.1K | 84,046 | D | ↗ |
| 2025-09-15 | Mano Michael | Officer | S-Sale | D | Common Stock | 234 | 6.43 | 1.5K | 21,425 | D | ↗ |
| 2025-09-15 | Cheng Sohanya Roshan | Officer | S-Sale | D | Common Stock | 325 | 6.43 | 2.1K | 35,856 | D | ↗ |
| 2025-09-15 | Abate Kristin | Officer | S-Sale | D | Common Stock | 23 | 6.43 | 147.89 | 10,408 | D | ↗ |
| 2025-09-12 | Rangwala Reshma | Officer | A-Award | A | Common Stock | 945 | 0.00 | — | 29,798 | D | ↗ |
| 2025-09-12 | Poulton Stuart | Officer | A-Award | A | Common Stock | 888 | 0.00 | — | 28,111 | D | ↗ |
| 2025-09-12 | Paulson Richard A. | Director / Officer | A-Award | A | Common Stock | 2,800 | 0.00 | — | 85,303 | D | ↗ |
| 2025-09-12 | Mano Michael | Officer | A-Award | A | Common Stock | 612 | 0.00 | — | 21,659 | D | ↗ |
| 2025-09-12 | Cheng Sohanya Roshan | Officer | A-Award | A | Common Stock | 945 | 0.00 | — | 36,181 | D | ↗ |
| 2025-09-12 | Abate Kristin | Officer | A-Award | A | Common Stock | 46 | 0.00 | — | 10,431 | D | ↗ |
| 2025-09-03 | Abate Kristin | Officer | S-Sale | D | Common Stock | 12 | 6.78 | 81.36 | 9,463 | D | ↗ |
| 2025-07-29 | Poulton Stuart | Officer | S-Sale | D | Common Stock | 191 | 4.37 | 834.67 | 27,223 | D | ↗ |
| 2025-07-22 | Abate Kristin | Officer | S-Sale | D | Common Stock | 238 | 4.00 | 952.00 | 9,475 | D | ↗ |
| 2025-05-28 | Su Zhen | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 4,600 | 4.48 | 20.6K | 4,600 | D | ↗ |
| 2025-05-28 | Schor Chen | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 4,600 | 4.48 | 20.6K | 4,600 | D | ↗ |
| 2025-05-28 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 4,600 | 4.48 | 20.6K | 4,600 | D | ↗ |
| 2025-05-28 | Oliger Christy J. | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 4,600 | 4.48 | 20.6K | 4,600 | D | ↗ |
| 2025-05-28 | Mirza Mansoor Raza | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 4,600 | 4.48 | 20.6K | 4,600 | D | ↗ |
| 2025-05-28 | Greene Barry E | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 4,600 | 4.48 | 20.6K | 4,600 | D | ↗ |
| 2025-05-28 | BOHLIN GAREN G | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 4,600 | 4.48 | 20.6K | 4,600 | D | ↗ |
| 2025-05-06 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 236 | 7.12 | 1.7K | 82,503 | D | ↗ |
| 2025-04-23 | Rangwala Reshma | Officer | S-Sale | D | Common Stock | 419 | 6.17 | 2.6K | 28,853 | D | ↗ |
| 2025-04-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 245 | 3.74 | 916.30 | 82,739 | D | ↗ |
| 2025-03-04 | Mano Michael | Officer | S-Sale | D | Common Stock | 2,793 | 6.29 | 17.6K | 21,047 | D | ↗ |
| 2025-02-28 | Rangwala Reshma | Officer | A-Award | A | Common Stock | 5,416 | 0.00 | — | 28,276 | D | ↗ |
| 2025-02-28 | Poulton Stuart | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 7.95 | 79.5K | 10,000 | D | ↗ |
| 2025-02-28 | Paulson Richard A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 7.95 | 318.0K | 40,000 | D | ↗ |
| 2025-02-28 | Mano Michael | Officer | A-Award | A | Common Stock | 2,250 | 0.00 | — | 23,840 | D | ↗ |
| 2025-02-28 | Cheng Sohanya Roshan | Officer | A-Award | A | Stock Option (right to buy) | 9,166 | 7.95 | 72.9K | 9,166 | D | ↗ |
| 2025-02-28 | Abate Kristin | Officer | A-Award | A | Common Stock | 933 | 0.00 | — | 10,284 | D | ↗ |
| 2025-02-18 | Poulton Stuart | Officer | S-Sale | D | Common Stock | 5,914 | 0.63 | 3.7K | 320,714 | D | ↗ |
| 2025-02-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 4,099 | 0.65 | 2.7K | 1,120,158 | D | ↗ |
| 2025-01-31 | Macomber Lori | Officer | A-Award | A | Stock Option (right to buy) | 650,000 | 0.62 | 404.4K | 650,000 | D | ↗ |
| 2025-01-06 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 4,055 | 0.78 | 3.2K | 1,124,257 | D | ↗ |
| 2025-01-03 | Macomber Lori | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,620 | 0.81 | 2.9K | 1,128,312 | D | ↗ |
| 2024-11-06 | Abate Kristin | Officer | — | — | Common Stock | 0 | 0.00 | — | 140,300 | D | ↗ |
| 2024-11-05 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,675 | 0.91 | 3.3K | 1,131,932 | D | ↗ |
| 2024-10-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,607 | 0.88 | 3.2K | 1,135,607 | D | ↗ |
| 2024-09-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,667 | 0.72 | 2.6K | 1,139,214 | — | ↗ |
| 2024-09-04 | Mason Michael | Officer | S-Sale | D | Common Stock | 7,050 | 0.72 | 5.1K | 391,054 | — | ↗ |
| 2024-09-04 | Mano Michael | Officer | S-Sale | D | Common Stock | 3,971 | 0.72 | 2.9K | 273,881 | — | ↗ |
| 2024-09-04 | Cheng Sohanya Roshan | Officer | S-Sale | D | Common Stock | 5,356 | 0.72 | 3.9K | 404,051 | — | ↗ |
| 2024-08-06 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,608 | 0.93 | 3.4K | 1,142,881 | — | ↗ |
| 2024-07-30 | Poulton Stuart | Officer | S-Sale | D | Common Stock | 2,883 | 1.06 | 3.1K | 326,628 | — | ↗ |
| 2024-07-05 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,616 | 0.85 | 3.1K | 1,146,489 | — | ↗ |
| 2024-06-07 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 2,240 | 0.95 | 2.1K | 0 | — | ↗ |
| 2024-06-06 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 117,307 | 0.98 | 115.3K | 229,308 | — | ↗ |
| 2024-06-05 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 463,518 | 0.96 | 444.1K | 346,615 | — | ↗ |
| 2024-06-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,592 | 0.99 | 3.6K | 1,150,105 | — | ↗ |
| 2024-06-04 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 337,742 | 0.95 | 321.6K | 810,133 | — | ↗ |
| 2024-06-04 | Mason Michael | Officer | S-Sale | D | Common Stock | 652 | 0.99 | 645.48 | 398,104 | — | ↗ |
| 2024-06-03 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 3,488 | 1.00 | 3.5K | 11,209 | — | ↗ |
| 2024-05-31 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 202,418 | 0.95 | 193.1K | 1,505,131 | — | ↗ |
| 2024-05-29 | Su Zhen | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 50,587 | 0.96 | 48.6K | 50,587 | — | ↗ |
| 2024-05-29 | Schor Chen | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 69,000 | 0.96 | 66.2K | 69,000 | — | ↗ |
| 2024-05-29 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 69,000 | 0.96 | 66.2K | 69,000 | — | ↗ |
| 2024-05-29 | Oliger Christy J. | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 69,000 | 0.96 | 66.2K | 69,000 | — | ↗ |
| 2024-05-29 | Mirza Mansoor Raza | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 69,000 | 0.96 | 66.2K | 69,000 | — | ↗ |
| 2024-05-29 | Greene Barry E | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 69,000 | 0.96 | 66.2K | 69,000 | — | ↗ |
| 2024-05-29 | BOHLIN GAREN G | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 69,000 | 0.96 | 66.2K | 69,000 | — | ↗ |
| 2024-05-06 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,576 | 1.13 | 4.0K | 1,153,697 | — | ↗ |
| 2024-04-22 | Rangwala Reshma | Officer | S-Sale | D | Common Stock | 6,789 | 1.17 | 7.9K | 342,931 | — | ↗ |
| 2024-04-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,563 | 1.29 | 4.6K | 1,157,273 | — | ↗ |
| 2024-03-05 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,573 | 1.30 | 4.6K | 1,160,836 | — | ↗ |
| 2024-03-01 | Rangwala Reshma | Officer | S-Sale | D | Common | 5,969 | 1.20 | 7.2K | 349,720 | — | ↗ |
| 2024-03-01 | Poulton Stuart | Officer | S-Sale | D | Common | 6,155 | 1.20 | 7.4K | 329,511 | — | ↗ |
| 2024-03-01 | Paulson Richard A. | Director / Officer | S-Sale | D | Common | 19,374 | 1.20 | 23.2K | 1,164,409 | — | ↗ |
| 2024-03-01 | Mason Michael | Officer | S-Sale | D | Common | 6,162 | 1.20 | 7.4K | 398,756 | — | ↗ |
| 2024-03-01 | Mano Michael | Officer | S-Sale | D | Common | 3,576 | 1.20 | 4.3K | 277,852 | — | ↗ |
| 2024-03-01 | Cheng Sohanya Roshan | Officer | S-Sale | D | Common | 5,109 | 1.20 | 6.1K | 393,509 | — | ↗ |
| 2024-02-29 | Rangwala Reshma | Officer | S-Sale | D | Common | 15,667 | 1.17 | 18.3K | 355,689 | — | ↗ |
| 2024-02-29 | Poulton Stuart | Officer | S-Sale | D | Common | 16,311 | 1.17 | 19.1K | 335,666 | — | ↗ |
| 2024-02-29 | Paulson Richard A. | Director / Officer | S-Sale | D | Common | 80,470 | 1.17 | 94.1K | 1,183,783 | — | ↗ |
| 2024-02-29 | Mason Michael | Officer | S-Sale | D | Common | 27,687 | 1.17 | 32.4K | 404,918 | — | ↗ |
| 2024-02-29 | Mano Michael | Officer | S-Sale | D | Common | 16,973 | 1.17 | 19.9K | 281,428 | — | ↗ |
| 2024-02-29 | Cheng Sohanya Roshan | Officer | S-Sale | D | Common | 21,840 | 1.17 | 25.6K | 398,618 | — | ↗ |
| 2024-02-28 | Rangwala Reshma | Officer | A-Award | A | Common Stock | 198,959 | 0.00 | — | 371,356 | — | ↗ |
| 2024-02-28 | Poulton Stuart | Officer | A-Award | A | Common Stock | 188,205 | 0.00 | — | 351,977 | — | ↗ |
| 2024-02-28 | Paulson Richard A. | Director / Officer | A-Award | A | Common Stock | 442,800 | 0.00 | — | 1,264,253 | — | ↗ |
| 2024-02-28 | Mason Michael | Officer | A-Award | A | Common Stock | 188,205 | 0.00 | — | 432,605 | — | ↗ |
| 2024-02-28 | Mano Michael | Officer | A-Award | A | Common Stock | 147,000 | 0.00 | — | 298,401 | — | ↗ |
| 2024-02-28 | Cheng Sohanya Roshan | Officer | A-Award | A | Common Stock | 198,959 | 0.00 | — | 420,458 | — | ↗ |
| 2024-02-27 | Mason Michael | Officer | S-Sale | D | Common Stock | 2,545 | 1.32 | 3.4K | 244,400 | — | ↗ |
| 2024-02-15 | Poulton Stuart | Officer | S-Sale | D | Common Stock | 5,748 | 1.33 | 7.6K | 163,871 | — | ↗ |
| 2024-02-06 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 4,012 | 1.59 | 6.4K | 821,453 | — | ↗ |
| 2024-02-06 | Mason Michael | Officer | S-Sale | D | Common Stock | 4,205 | 1.59 | 6.7K | 246,945 | — | ↗ |
| 2024-01-24 | Rangwala Reshma | Officer | A-Award | A | Common Stock | 14,167 | 0.00 | — | 172,397 | — | ↗ |
| 2024-01-24 | Poulton Stuart | Officer | A-Award | A | Common Stock | 13,333 | 0.00 | — | 169,619 | — | ↗ |
| 2024-01-24 | Paulson Richard A. | Director / Officer | A-Award | A | Common Stock | 42,000 | 0.00 | — | 825,465 | — | ↗ |
| 2024-01-24 | Mason Michael | Officer | A-Award | A | Common Stock | 13,333 | 0.00 | — | 251,150 | — | ↗ |
| 2024-01-24 | Mano Michael | Officer | A-Award | A | Common Stock | 9,167 | 0.00 | — | 151,401 | — | ↗ |
| 2024-01-24 | Cheng Sohanya Roshan | Officer | A-Award | A | Common Stock | 14,167 | 0.00 | — | 221,499 | — | ↗ |
| 2024-01-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 4,114 | 0.82 | 3.4K | 783,465 | — | ↗ |
| 2023-12-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,622 | 0.79 | 2.9K | 787,579 | — | ↗ |
| 2023-11-06 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,606 | 0.92 | 3.3K | 791,201 | — | ↗ |
| 2023-10-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,589 | 1.27 | 4.6K | 794,807 | — | ↗ |
| 2023-09-12 | BOHLIN GAREN G | Director | P-Purchase | A | Common Stock | 41,140 | 1.22 | 50.0K | 45,140 | — | ↗ |
| 2023-09-05 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,558 | 1.33 | 4.7K | 798,460 | — | ↗ |
| 2023-09-01 | Mason Michael | Officer | S-Sale | D | Common Stock | 6,913 | 1.33 | 9.2K | 237,817 | — | ↗ |
| 2023-09-01 | Mano Michael | Officer | S-Sale | D | Common Stock | 3,888 | 1.33 | 5.2K | 142,234 | — | ↗ |
| 2023-09-01 | Cheng Sohanya Roshan | Officer | S-Sale | D | Common Stock | 7,415 | 1.33 | 9.9K | 204,086 | — | ↗ |
| 2023-08-31 | Su Zhen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-07 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,722 | 1.72 | 6.4K | 802,018 | — | ↗ |
| 2023-07-28 | Poulton Stuart | Officer | S-Sale | D | Common Stock | 2,845 | 1.70 | 4.8K | 156,286 | — | ↗ |
| 2023-07-05 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,538 | 1.72 | 6.1K | 805,740 | — | ↗ |
| 2023-06-08 | Cheng Sohanya Roshan | Officer | S-Sale | D | Common Stock | 1,839 | 2.35 | 4.3K | 211,501 | — | ↗ |
| 2023-06-05 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,536 | 2.24 | 7.9K | 809,278 | — | ↗ |
| 2023-06-02 | Mason Michael | Officer | S-Sale | D | Common Stock | 631 | 2.22 | 1.4K | 244,730 | — | ↗ |
| 2023-05-24 | Schor Chen | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 34,000 | 2.50 | 85.0K | 34,000 | — | ↗ |
| 2023-05-24 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 34,000 | 2.50 | 85.0K | 34,000 | — | ↗ |
| 2023-05-24 | Oliger Christy J. | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 34,000 | 2.50 | 85.0K | 34,000 | — | ↗ |
| 2023-05-24 | Mirza Mansoor Raza | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 34,000 | 2.50 | 85.0K | 34,000 | — | ↗ |
| 2023-05-24 | Honig Peter | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 34,000 | 2.50 | 85.0K | 34,000 | — | ↗ |
| 2023-05-24 | Greene Barry E | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 34,000 | 2.50 | 85.0K | 34,000 | — | ↗ |
| 2023-05-24 | BOHLIN GAREN G | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 34,000 | 2.50 | 85.0K | 34,000 | — | ↗ |
| 2023-05-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,805 | 3.35 | 12.8K | 812,814 | — | ↗ |
| 2023-04-20 | Rangwala Reshma | Officer | S-Sale | D | Common Stock | 115 | 4.03 | 463.07 | 164,885 | — | ↗ |
| 2023-04-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,497 | 3.97 | 13.9K | 816,619 | — | ↗ |
| 2023-03-06 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,506 | 3.16 | 11.1K | 820,116 | — | ↗ |
| 2023-03-01 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 33,033 | 3.03 | 100.1K | 823,622 | — | ↗ |
| 2023-03-01 | Mitchener Stephen | Officer | S-Sale | D | Common Stock | 6,357 | 3.03 | 19.3K | 128,313 | — | ↗ |
| 2023-03-01 | Mason Michael | Officer | S-Sale | D | Common Stock | 11,205 | 3.03 | 33.9K | 245,361 | — | ↗ |
| 2023-03-01 | Mano Michael | Officer | S-Sale | D | Common Stock | 6,878 | 3.03 | 20.8K | 146,122 | — | ↗ |
| 2023-03-01 | Cheng Sohanya Roshan | Officer | S-Sale | D | Common Stock | 11,239 | 3.03 | 34.0K | 210,687 | — | ↗ |
| 2023-02-28 | Rangwala Reshma | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 165,000 | — | ↗ |
| 2023-02-28 | Poulton Stuart | Officer | A-Award | A | Common Stock | 95,000 | 0.00 | — | 159,131 | — | ↗ |
| 2023-02-28 | Paulson Richard A. | Director / Officer | A-Award | A | Common Stock | 252,000 | 0.00 | — | 856,655 | — | ↗ |
| 2023-02-28 | Mitchener Stephen | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 134,670 | — | ↗ |
| 2023-02-28 | Mason Michael | Officer | A-Award | A | Common Stock | 95,000 | 0.00 | — | 256,566 | — | ↗ |
| 2023-02-28 | Mano Michael | Officer | A-Award | A | Common Stock | 70,000 | 0.00 | — | 153,000 | — | ↗ |
| 2023-02-28 | Cheng Sohanya Roshan | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 221,926 | — | ↗ |
| 2023-02-27 | Mason Michael | Officer | S-Sale | D | Common Stock | 2,802 | 3.04 | 8.5K | 161,566 | — | ↗ |
| 2023-02-15 | Poulton Stuart | Officer | S-Sale | D | Common Stock | 196 | 3.16 | 619.36 | 64,131 | — | ↗ |
| 2023-02-06 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 3,950 | 3.40 | 13.4K | 604,655 | — | ↗ |
| 2023-02-06 | Mason Michael | Officer | S-Sale | D | Common Stock | 4,141 | 3.40 | 14.1K | 164,368 | — | ↗ |
| 2023-01-04 | Paulson Richard A. | Officer | S-Sale | D | Common Stock | 3,922 | 3.27 | 12.8K | 608,605 | — | ↗ |
| 2022-12-05 | Paulson Richard A. | Officer | S-Sale | D | Common Stock | 3,490 | 5.17 | 18.0K | 612,527 | — | ↗ |
| 2022-11-04 | Paulson Richard A. | Officer | S-Sale | D | Common Stock | 3,493 | 4.54 | 15.9K | 616,017 | — | ↗ |
| 2022-10-04 | Paulson Richard A. | Officer | S-Sale | D | Common Stock | 3,488 | 5.87 | 20.5K | 619,510 | — | ↗ |
| 2022-09-08 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 16 | 5.26 | 84.10 | 626,461 | — | ↗ |
| 2022-08-31 | Mitchener Stephen | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 70,546 | — | ↗ |
| 2022-08-31 | Mason Michael | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 168,509 | — | ↗ |
| 2022-08-31 | Mano Michael | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-08-31 | Cheng Sohanya Roshan | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 119,949 | — | ↗ |
| 2022-08-15 | Poulton Stuart | Officer | — | D | Stock Option (right to buy) | 65,000 | 10.33 | 671.5K | 0 | — | ↗ |
| 2022-08-11 | Greene Barry E | Director | M-Exempt | A | Common Stock | 7,576 | 1.49 | 11.3K | 13,606 | — | ↗ |
| 2022-08-04 | Paulson Richard A. | Officer | S-Sale | D | Common Stock | 2,314 | 4.48 | 10.4K | 626,477 | — | ↗ |
| 2022-07-08 | Paulson Richard A. | Officer | S-Sale | D | Common Stock | 2,115 | 5.18 | 10.9K | 628,791 | — | ↗ |
| 2022-06-13 | Cheng Sohanya Roshan | Officer | S-Sale | D | Common Stock | 66 | 5.35 | 352.77 | 91,434 | — | ↗ |
| 2022-06-10 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 1,294 | 6.00 | 7.8K | 1,707,549 | — | ↗ |
| 2022-06-09 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 209,455 | 6.18 | 1.29M | 1,708,843 | — | ↗ |
| 2022-06-08 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 322,825 | 6.50 | 2.10M | 1,918,298 | — | ↗ |
| 2022-06-07 | Paulson Richard A. | Officer | S-Sale | D | Common Stock | 2,542 | 5.76 | 14.6K | 630,906 | — | ↗ |
| 2022-06-03 | Mason Michael | Officer | S-Sale | D | Common Stock | 598 | 6.04 | 3.6K | 138,512 | — | ↗ |
| 2022-05-19 | Schor Chen | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 23,900 | 5.65 | 135.0K | 23,900 | — | ↗ |
| 2022-05-19 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 23,900 | 0.00 | — | 23,900 | — | ↗ |
| 2022-05-19 | Oliger Christy J. | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 23,900 | 0.00 | — | 23,900 | — | ↗ |
| 2022-05-19 | Mirza Mansoor Raza | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 23,900 | 0.00 | — | 23,900 | — | ↗ |
| 2022-05-19 | Honig Peter | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 10,995 | 0.00 | — | 10,995 | — | ↗ |
| 2022-05-19 | Greene Barry E | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 23,900 | 5.65 | 135.0K | 23,900 | — | ↗ |
| 2022-05-19 | BOHLIN GAREN G | Director | A-Award | A | Nonstatutory Stock Option (right to buy) | 23,900 | 0.00 | — | 23,900 | — | ↗ |
| 2022-05-04 | Paulson Richard A. | Director / Officer | S-Sale | D | Common Stock | 633 | 6.26 | 4.0K | 661,317 | — | ↗ |
| 2022-04-29 | Rangwala Reshma | Officer | A-Award | A | Common Stock | 65,000 | 0.00 | — | 65,000 | — | ↗ |
| 2022-04-19 | Rangwala Reshma | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-29 | Shacham Sharon | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 0.00 | — | 90,000 | — | ↗ |
| 2022-02-28 | Shacham Sharon | Officer | A-Award | A | Stock Option (right to buy) | 27,000 | 10.33 | 278.9K | 27,000 | — | ↗ |
| 2022-02-28 | Paulson Richard A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 360,000 | 10.33 | 3.72M | 360,000 | — | ↗ |
| 2022-02-28 | Mitchener Stephen | Officer | A-Award | A | Common Stock | 47,250 | 0.00 | — | 50,546 | — | ↗ |
| 2022-02-28 | Mason Michael | Officer | A-Award | A | Stock Option (right to buy) | 111,600 | 10.33 | 1.15M | 111,600 | — | ↗ |
| 2022-02-28 | Mano Michael | Officer | A-Award | A | Common Stock | 63,000 | 0.00 | — | 63,000 | — | ↗ |
| 2022-02-28 | Kauffman Michael | Director | A-Award | A | Common Stock | 21,000 | 0.00 | — | 719,983 | — | ↗ |
| 2022-02-28 | Frenkel Ran | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 10.33 | 929.7K | 90,000 | — | ↗ |
| 2022-02-28 | Cheng Sohanya Roshan | Officer | A-Award | A | Common Stock | 84,000 | 0.00 | — | 91,500 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-325.1K
Shares Outstanding
8.54M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Richard Paulson President and Chief Executive Officer | 770.0K | 100.1K | 839.0K | 241.5K | 350.4K | 19.9K | 2.32M | 46.56% | ↗ |
| 2 | 2025 | Reshma Rangwala Chief Medical Officer and Head of Research | 567.7K | 1.05M | 79.5K | 120.8K | 178.8K | 18.2K | 2.02M | 9.93% | ↗ |
| 3 | 2025 | Stuart Poulton Executive Vice President, Chief Development Officer | 500.1K | 295.0K | 312.3K | 115.7K | 157.5K | 18.9K | 1.40M | 30.58% | ↗ |
| 4 | 2024 | Richard Paulson President and Chief Executive Officer | 769.6K | — | 854.6K | — | 425.4K | 19.7K | 2.07M | 41.30% | ↗ |
| 5 | 2024 | Reshma Rangwala Chief Medical Officer and Head of Research | 567.7K | — | 315.8K | — | 222.9K | 18.0K | 1.12M | 28.08% | ↗ |
| 6 | 2024 | Sohanya Cheng Chief Commercial Officer and Head of Business Development | 546.0K | — | 315.8K | — | 214.4K | 18.7K | 1.09M | 28.84% | ↗ |
| 7 | 2023 | Richard Paulson President and Chief Executive Officer | 740.0K | 200.0K | 1.20M | — | 457.0K | 28.1K | 2.63M | 45.74% | ↗ |
| 8 | 2023 | Reshma Rangwala Chief Medical Officer and Head of Research | 545.9K | — | 450.5K | — | 210.7K | 20.7K | 1.23M | 36.69% | ↗ |
| 9 | 2023 | Sohanya Cheng Chief Commercial Officer and Head of Business Development | 513.7K | — | 450.5K | — | 202.7K | 26.6K | 1.19M | 37.75% | ↗ |
| 10 | 2023 | Sohanya Cheng Chief Commercial Officer | 513.7K | — | 450.5K | — | 202.7K | 26.6K | 1.19M | 37.75% | ↗ |
| 11 | 2023 | Michael Mason Chief Financial Officer | 500.3K | — | 426.6K | — | 191.6K | 20.7K | 1.14M | 37.45% | ↗ |
| 12 | 2023 | Stuart Poulton Chief Development Officer | 477.0K | — | 426.6K | — | 184.1K | 21.4K | 1.11M | 38.47% | ↗ |
| 13 | 2022 | Richard Paulson President and Chief Executive Officer | 696.8K | 200.0K | 2.98M | 2.56M | 452.9K | 14.5K | 6.91M | 80.26% | ↗ |
| 14 | 2022 | Sharon Shacham Former Chief Scientific Officer | 211.9K | — | 1.22M | 3.41M | 108.3K | 1.08M | 6.04M | 76.74% | ↗ |
| 15 | 2022 | Michael Mason Chief Financial Officer | 472.0K | — | 1.06M | 954.5K | 193.0K | 16.5K | 2.70M | 74.75% | ↗ |
| 16 | 2022 | Sohanya Cheng Chief Commercial Officer | 457.3K | — | 1.02M | 928.9K | 193.0K | 13.9K | 2.61M | 74.57% | ↗ |
| 17 | 2022 | Ran Frenkel Former Chief Development Officer | 279.4K | — | 705.0K | 640.7K | — | 535.1K | 2.16M | 62.30% | ↗ |
| 18 | 2022 | Michael Mano General Counsel | 427.3K | — | 752.0K | 683.3K | 184.1K | 13.7K | 2.06M | 69.66% | ↗ |
| 19 | 2022 | Stuart Poulton Chief Development Officer | 373.9K | 50.0K | 580.1K | 610.0K | 168.7K | 12.6K | 1.80M | 66.29% | ↗ |
| 20 | 2021 | Richard Paulson President and Chief Executive Officer | 468.4K | 300.0K | 3.52M | 3.56M | 435.5K | 64.7K | 8.36M | 84.82% | ↗ |
| 21 | 2021 | Richard Paulson, M.B.A. President and Chief Executive Officer | 468.4K | 300.0K | 3.52M | 3.56M | 435.5K | 64.7K | 8.36M | 84.82% | ↗ |
| 22 | 2021 | Sharon Shacham Former Chief Scientific Officer | 499.9K | — | 832.8K | 1.51M | 250.0K | 16.7K | 3.11M | 75.33% | ↗ |
| 23 | 2021 | Sharon Shacham, Ph.D., M.B.A. Chief Scientific Officer and Former President | 499.9K | — | 832.8K | 1.51M | 250.0K | 16.7K | 3.11M | 75.33% | ↗ |
| 24 | 2021 | Michael G. Kauffman, M.D., Ph.D. Senior Clinical Advisor and Former Chief Executive Officer | 474.4K | — | 832.8K | 1.51M | 237.2K | 18.0K | 3.07M | 76.23% | ↗ |
| 25 | 2021 | Michael Mason, M.B.A., C.P.A. Executive Vice President, Chief Financial Officer and Treasurer | 444.4K | 50.0K | 370.8K | 681.4K | 182.0K | 16.0K | 1.74M | 60.31% | ↗ |
| 26 | 2021 | Michael Mason Chief Financial Officer | 444.4K | 50.0K | 370.8K | 681.4K | 182.0K | 16.0K | 1.74M | 60.31% | ↗ |
| 27 | 2021 | Jatin Shah, M.D. Former Executive Vice President, Chief Medical Officer | 458.0K | — | 320.5K | 588.8K | 179.1K | 41.8K | 1.59M | 57.26% | ↗ |
| 28 | 2021 | Ran Frenkel Former Chief Development Officer | 429.5K | 50.0K | 320.5K | 588.8K | 172.0K | 16.3K | 1.58M | 57.65% | ↗ |
| 29 | 2021 | Ran Frenkel, RPh. Executive Vice President, Chief Development Officer | 429.5K | 50.0K | 320.5K | 588.8K | 172.0K | 16.3K | 1.58M | 57.65% | ↗ |
| 30 | 2020 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 625.6K | — | 1.03M | 1.92M | 348.8K | 11.9K | 3.94M | 74.95% | ↗ |
| 31 | 2020 | Michael G. Kauffman, M.D., Ph.D. Senior Clinical Advisor and Former Chief Executive Officer | 625.6K | — | 1.03M | 1.92M | 348.8K | 11.9K | 3.94M | 74.95% | ↗ |
| 32 | 2020 | Sharon Shacham, Ph.D., M.B.A. Chief Scientific Officer and Former President | 483.6K | — | 1.03M | 1.92M | 224.6K | 11.9K | 3.67M | 80.38% | ↗ |
| 33 | 2020 | Sharon Shacham Former Chief Scientific Officer | 483.6K | — | 1.03M | 1.92M | 224.6K | 11.9K | 3.67M | 80.38% | ↗ |
| 34 | 2020 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 483.6K | — | 1.03M | 1.92M | 224.6K | 11.9K | 3.67M | 80.38% | ↗ |
| 35 | 2020 | Michael Mason, M.B.A., C.P.A. Executive Vice President, Chief Financial Officer and Treasurer | 415.6K | — | 587.0K | 1.10M | 156.1K | 11.9K | 2.27M | 74.25% | ↗ |
| 36 | 2020 | Michael Mason Chief Financial Officer | 415.6K | — | 587.0K | 1.10M | 156.1K | 11.9K | 2.27M | 74.25% | ↗ |
| 37 | 2020 | Michael Mason, M.B.A., C.P.A. Senior Vice President, Chief Financial Officer and Treasurer | 415.6K | — | 587.0K | 1.10M | 156.1K | 11.9K | 2.27M | 74.25% | ↗ |
| 38 | 2019 | Michael G. Kauffman, M.D., Ph.D. Senior Clinical Advisor and Former Chief Executive Officer | 566.5K | — | 803.1K | 1.49M | 363.7K | 11.9K | 3.23M | 70.85% | ↗ |
| 39 | 2019 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 566.5K | — | 803.1K | 1.49M | 363.7K | 11.9K | 3.23M | 70.85% | ↗ |
| 40 | 2019 | Sharon Shacham, Ph.D., M.B.A. Chief Scientific Officer and Former President | 468.5K | — | 803.1K | 1.49M | 250.6K | 11.9K | 3.02M | 75.80% | ↗ |
| 41 | 2019 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 468.5K | — | 803.1K | 1.49M | 250.6K | 11.9K | 3.02M | 75.80% | ↗ |
| 42 | 2019 | Christopher B. Primiano, J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | 418.2K | — | 356.4K | 660.9K | 176.0K | 11.9K | 1.62M | 62.67% | ↗ |
| 43 | 2019 | Michael Mason, M.B.A., C.P.A. Senior Vice President, Chief Financial Officer and Treasurer | 340.3K | — | — | 529.9K | 75.0K | 11.4K | 956.7K | 55.39% | ↗ |
| 44 | 2019 | Michael Mason, M.B.A., C.P.A. Executive Vice President, Chief Financial Officer and Treasurer | 340.3K | — | — | 529.9K | 75.0K | 11.4K | 956.7K | 55.39% | ↗ |
| 45 | 2018 | Anand Varadan, M.B.A. Executive Vice President, Chief Commercial Officer | 211.8K | 25.0K | — | 1.95M | 102.3K | 11.4K | 2.30M | 84.78% | ↗ |
| 46 | 2018 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 550.0K | — | — | 1.44M | 268.6K | 11.7K | 2.27M | 63.50% | ↗ |
| 47 | 2018 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 450.0K | — | — | 1.44M | 183.1K | 11.7K | 2.09M | 69.14% | ↗ |
| 48 | 2018 | Christopher B. Primiano, J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | 404.0K | — | — | 902.9K | 204.0K | 11.7K | 1.52M | 59.30% | ↗ |
| 49 | 2018 | Michael Falvey, M.S.M. Former Executive Vice President, Chief Financial Officer and Treasurer | 404.0K | — | — | 686.2K | 173.4K | 11.7K | 1.28M | 53.81% | ↗ |
| 50 | 2017 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 530.5K | — | — | 1.86M | 251.5K | 11.5K | 2.65M | 70.07% | ↗ |
| 51 | 2017 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 435.0K | — | — | 1.86M | 171.9K | 11.5K | 2.48M | 75.03% | ↗ |
| 52 | 2017 | Christopher B. Primiano, J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | 390.0K | 31.5K | — | 876.8K | 133.8K | 11.5K | 1.44M | 60.74% | ↗ |
| 53 | 2016 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 515.0K | — | — | 758.5K | 247.2K | 11.3K | 1.53M | 49.51% | ↗ |
| 54 | 2016 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 415.0K | — | — | 758.5K | 166.0K | 11.3K | 1.35M | 56.15% | ↗ |
| 55 | 2016 | Justin A. Renz, C.P.A., M.S.T., M.B.A. Former Executive Vice President, Chief Financial Officer & Treasurer | 360.0K | — | — | 446.2K | 114.1K | 11.3K | 931.6K | 47.90% | ↗ |
| 56 | 2016 | Christopher B. Primiano, J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | 360.0K | — | — | 178.5K | 122.0K | 11.3K | 671.7K | 26.57% | ↗ |
| 57 | 2015 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 500.0K | — | — | 3.90M | 150.0K | 11.0K | 4.56M | 85.50% | ↗ |
| 58 | 2015 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 412.0K | — | — | 3.90M | 103.0K | 11.0K | 4.42M | 88.11% | ↗ |
| 59 | 2015 | Christopher B. Primiano, J.D., M.B.A. Senior Vice President, Corporate Development, General Counsel and Secretary | 333.6K | — | 537.3K | 3.22M | 100.2K | 11.0K | 4.20M | 89.41% | ↗ |
| 60 | 2015 | Justin A. Renz, C.P.A., M.S.T., M.B.A. Former Executive Vice President, Chief Financial Officer & Treasurer | 355.0K | — | 537.3K | 876.7K | 85.2K | 11.0K | 1.87M | 75.81% | ↗ |
| 61 | 2015 | Justin A. Renz, C.P.A., M.S.T., M.B.A. Executive Vice President, Chief Financial Officer & Treasurer | 355.0K | — | 537.3K | 876.7K | 85.2K | 11.0K | 1.87M | 75.81% | ↗ |
| 62 | 2014 | Justin A. Renz, C.P.A., M.S.T., M.B.A. Executive Vice President, Chief Financial Officer Treasurer | 129.4K | — | — | 10.03M | 36.0K | 157.00 | 10.20M | 98.38% | ↗ |
| 63 | 2014 | Justin A. Renz, C.P.A., M.S.T., M.B.A. Executive Vice President, Chief Financial Officer & Treasurer | 129.4K | — | — | 7.70M | 36.0K | 157.00 | 7.87M | 97.90% | ↗ |
| 64 | 2014 | Ran Frenkel, RPh. | 64.2K | — | — | 6.39M | 15.6K | 10.1K | 6.48M | 98.61% | ↗ |
| 65 | 2014 | Christopher B. Primiano, J.D., M.B.A. Senior Vice President, Corporate Development, General Counsel and Secretary | 213.8K | — | — | 1.87M | 60.5K | 8.0K | 2.15M | 86.90% | ↗ |
| 66 | 2014 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 440.0K | — | — | — | 198.0K | 10.8K | 648.8K | 0.00% | ↗ |
| 67 | 2014 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 440.0K | — | — | — | 198.0K | 10.8K | 648.8K | 0.00% | ↗ |
| 68 | 2014 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 385.0K | — | — | — | 138.5K | 10.8K | 534.3K | 0.00% | ↗ |
| 69 | 2014 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 385.0K | — | — | — | 138.5K | 10.8K | 534.3K | 0.00% | ↗ |
| 70 | 2013 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 380.5K | — | — | 6.77M | 170.0K | 10.3K | 7.33M | 92.35% | ↗ |
| 71 | 2013 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 380.5K | — | — | 6.77M | 129.3K | 10.2K | 7.29M | 92.87% | ↗ |
| 72 | 2013 | Paul Brannelly Senior Vice President, Finance and | 160.5K | — | — | 1.70M | 118.0K | 4.6K | 1.99M | 85.75% | ↗ |
| 73 | 2012 | Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer | 352.2K | — | — | — | 97.9K | 13.1K | 463.3K | 0.00% | ↗ |
| 74 | 2012 | Sharon Shacham, Ph.D., M.B.A. President and Chief Scientific Officer | 300.0K | — | — | 5.5K | 138.8K | 12.1K | 456.3K | 1.20% | ↗ |
| 75 | 2012 | Paul Brannelly Senior Vice President, Finance and | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Reshma Rangwala | Executive Vice President, Chief Medical Officer & Head of Research | 2M | — |
| Sharon Shacham | Co-Founder & Chairman of Scientific Advisory Board | 1M | — |
| Richard A. Paulson | President, Chief Executive Officer & Director | 1M | male |
| Stuart Poulton | Executive Vice President & Chief Development Officer | 971.6K | male |
| Sohanya Cheng | Executive Vice President, Chief Commercial Officer & Head of Business Development | 779.0K | female |
| Lori A. Macomber | Executive Vice President, Chief Financial Officer & Treasurer | 712.7K | female |
| Michael J. Mano | Executive VP, Chief Legal Officer & Secretary | 625.1K | male |
| Lisa DiPaolo | Executive Vice President & Chief Human Resource Officer | — | female |
| Amama Sadiq | Senior Vice President of Global Medical & Scientific Affairs | — | — |
| James Accumanno | Chief Compliance Officer | — | male |
| Brian Austad | Senior Vice President of Pharmaceutical Sciences | — | male |
| Brendan Twohig Strong | Senior Vice President of Investor Relations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KPTI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
